This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Biofourmis , a global digitalhealth and clinical trial solutions leader, announces four key partnerships with top pharmaceutical firms. Beyond digital biomarker and endpoint expertise, pharmaceutical partners are leveraging Biofourmis to streamline study timelines through its Digital Clinical Trials solution.
Koneksa’s digital biomarker solutions include an industry-leading platform that gives research sponsors and clinical sites the ability to seamlessly aggregate data in real-time from devices, ePROs, patient diaries, and clinical assessments to provide the full picture of an individual’s health.
Spellman and Wortel are the most recent additions to Catawba Research’s team of scientific and regulatory advisors who support sponsors across a multitude of therapeutic areas and provide clinical development and regulatory strategy across North America, Europe and Asia.
Exec Summary: DigitalHealth is a subset of Healthtech. DigitalHealth focuses on the individual patient, while Healthtech focuses on the entire healthcare ecosystem. Artificial intelligence: This is a rapidly developing field that has the potential to revolutionize healthcare. Subscribe Today!
23andMe tried to monetize its extensive genetic database by collaborating with pharmaceutical companies for drug research. While promising, drugdevelopment requires significant time and investment, delaying any financial returns and impacting the company’s short-term revenue.
Hospitals and healthcare systems are increasingly implementing AI tools for tasks like medical imaging analysis, drug discovery, and even robot-assisted surgery. With this rapid adoption, there's a need for dedicated leadership to guide responsible and strategic implementation.
The increasing importance of digitalhealth, coupled with abundant capital and supportive regulatory environments, is likely to drive continued M&A activity and higher valuations. Regulatory Environment: Favourable regulatory policies and increased government support for digitalhealth initiatives are fostering innovation.
Biopharma Innovation and DrugDevelopment: The development of innovative drugs and therapies remains a key focus in the healthcare industry. Conference attendees discussed the latest trends in biopharma innovation, including gene therapy, cell therapy, and antibody-drug conjugates. Subscribe Today!
Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit [link] HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Public health: Studying the spread of infectious diseases and identifying risk factors.
Exec Summary: The HealthTech sector is poised for significant M&A activity in 2025, driven by several key trends: DigitalHealth Solutions: The increasing demand for digitalhealth solutions to improve healthcare accessibility and efficiency will drive acquisitions of innovative startups and established players in this space.
Corporate Development for Healthcare Technology companies in EMEA Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit [link] HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors.
These individuals have personally built leading technology platforms supercharging drugdevelopment globally. Their buy-in shows that our platform is differentiated and poised to unlock truly novel therapies for currently underserved patient populations through efficient, simulation-guided development. Jane Rhodes, Ph.D.,
It can be used to create new drugs, develop personalized treatment plans, and even generate synthetic medical data. HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, DigitalHealth Insights and Analysis. But how can healthcare organisations best leverage this technology? Subscribe Today!
Here are some key trends and developments to watch: Key Trends: Technological Advancements: New technologies are revolutionizing wound care, including advanced wound dressings, bioengineered skin substitutes, and innovative wound management devices. This shift towards digitalisation is improving patient outcomes and reducing healthcare costs.
AI and machine learning: Companies with advanced AI solutions for tasks like drug discovery, clinical trial optimisation, and personalised medicine can be attractive targets. Visit [link] HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Subscribe Today!
Digital Biology: Tools like BioNeMo utilise AI to analyse vast amounts of biological data, leading to breakthroughs in drugdevelopment and understanding of diseases. HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, DigitalHealth Insights and Analysis. Subscribe Today!
In the context of healthtech and digitalhealth, it means a company initially targets consumers (B2C), builds a strong user base, and then leverages this consumer adoption to attract businesses (B2B), such as insurers, employers, or healthcare providers. Exec Summary: B2C2B stands for Business-to-Consumer-to-Business.
Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit [link] HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Subscribe Today! Here are some key areas where we anticipate significant growth: 1.
Regulatory Hurdles: The stringent regulatory environment in healthcare can increase development costs and delay time to market, making it less attractive to investors. Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Subscribe Today! Subscribe Today!
HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, DigitalHealth Insights and Analysis. Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit www.nelsonadvisors.co.uk Subscribe Today! Email lloyd@nelsonadvisors.co.uk Subscribe Today!
Corporate Development for Healthcare Technology companies in EMEA Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit [link] HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors.
HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, DigitalHealth Insights and Analysis. Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit www.nelsonadvisors.co.uk Subscribe Today! Email lloyd@nelsonadvisors.co.uk Subscribe Today!
As these implementations take hold, the emphasis will be on demonstrating measurable return on investment (ROI), with AI driving down administrative burdens, accelerating drugdevelopment, and significantly improving operational efficiency. What’s most exciting to me is AI’s potential impact on personalized medicine.
Enhanced research efficiency: Researchers can gain faster access to anonymized patient data with patient consent through SSI, accelerating research efforts and drugdevelopment. Visit [link] HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors.
Corporate Development for Healthcare Technology companies in EMEA Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit [link] HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors.
This enables us to provide full support from our portfolio of services to all drugdevelopers, from formulation development to patient onboarding.” This collaboration further strengthens Aptar Pharma’s leadership in respiratory by offering a broader range of drug delivery formats, solutions and services.
We are excited to support Seamless Therapeutics in its pursuit of taking a leadership position in the rapidly evolving gene editing arena,” added Karl Nägler, PhD, Managing Partner at Wellington Partners. “At billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drugdevelopment.
Marcus Perez, President at Altera DigitalHealth In 2025, the public cloud will continue to play a pivotal role in healthcare’s evolution, driven by the demand for scalability, interoperability, and secure data management. This collaboration will drive innovations such as faster drugdevelopment and coordinated patient care.
Boost research and innovation: Researchers will have a secure platform to access and analyse large datasets for medical research, leading to advancements in disease prevention, treatment, and drugdevelopment. HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, DigitalHealth Insights and Analysis.
Healthcare Technology Thought Leadership from Nelson Advisors Market Insights, Analysis & Predictions. Visit [link] HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Even in drugdevelopment, happy accidents align with this idea.
The report includes recommendations to advance Americas leadership in AI innovation across multiple industries, and the healthcare section definitely packed a punch. leadership. The post House Task Force AI Policy Recommendations appeared first on DigitalHealth Wire.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content